Some genetics experts felt the event raised awareness of the importance of testing, while others had mixed feelings amid ...

The firm voluntarily retracted the BLA amid an effort to reprioritize its pipeline and is looking for partners to advance the program.

The partners aim to retrospectively identify predictive and prognostic breast cancer biomarkers using data from multiple randomized trials.

The firm said it expects a loss of ¥58.0 billion by discontinuing development its cell therapies, which are currently in preclinical phase.

The firm's lead candidate is a preclinical gene therapy for dry AMD, which it is advancing into IND-enabling studies.

NEW YORK – Sapienza University, Takis Biotech, and liquid biopsy company Tethis said on Friday they are teaming up to develop HER3-targeted therapies and companion diagnostics for lung cancer, with ...